Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310798 | 0.90 | MEN1 (0.32) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL16197723 | 0.78 | — | — | |
| SCHEMBL16197422 | 0.77 | NOS3 (0.38) | EPHX1 | |
| SCHEMBL6670962 | 0.77 | GABRP (0.41) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL6665323 | 0.75 | ALDH1A1 (0.35) | — | |
| SCHEMBL10830752 | 0.74 | CA12 (0.40) | MEN1KMT2A | |
| SCHEMBL20451587 | 0.72 | ACACB (0.41) | — | |
| SCHEMBL20451583 | 0.72 | ACACB (0.41) | — | |
| SCHEMBL29029803 | 0.72 | AKR1B1 (0.39) | MEN1KMT2A | |
| SCHEMBL21784362 | 0.72 | HDAC6 (0.36) | EPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | GOFF HILL LIMITED (BB) | 2012-02-09 | — | — | US | disclosed |
| EP-2403496-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | Goff Hill Limited (BB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | TP53, RNASE1, FURIN | EPHX1 484/4885MEN1 707/4885HTT 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.